Note 14 – Subsequent Events

Management of the Company has performed a review of events and transactions occurring after the consolidated balance sheet date to determine if there were any such events or transactions requiring adjustment to or disclosure in the accompanying consolidated financial statements, nothing other than the following:

In February 2026, the Company launched the Stemtech BioSciences e-commerce retail platform intended to expand retail distribution channels and increase consumer access to the Company’s products.

In April 2026, the Company secured financing to support the production of approximately $2.5 million of inventory intended to improve product availability and support anticipated customer demand. Post-Balance Sheet Equity Issuances: Between January 1, 2026 and March 31, 2026, the Company issued 1,223,835,979 shares of common stock, bringing total shares outstanding to 1,649,816,690 as of March 31, 2026, as verified by the Company’s transfer agent Empire Stock Transfer. These issuances were comprised entirely of conversions of outstanding convertible debt obligations by SOHO FO LLC and 1800 Diagonal Lending LLC pursuant to the terms of existing convertible note agreements; no cash proceeds were received by the Company. As of May 26, 2026, total shares outstanding were 2,067,960,034. The continued conversion of convertible debt into equity results in significant dilution to existing stockholders.